Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.
Hotta
Katsuyuki
K
Inoue
Akira
A
Kiura
Katsuyuki
K
Ueoka
Hiroshi
H
Nukiwa
Toshihiro
T
Tanimoto
Mitsune
M
D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000503:physiopathology; D000075202:Contraindications; D003556:Cystitis / Q000139:chemically induced / Q000453:epidemiology; D005240:Feasibility Studies; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000453:epidemiology; D000077156:Gefitinib; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000139:chemically induced / Q000453:epidemiology; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000453:epidemiology
D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib